Comparison of PDE 4 Inhibitors, Rolipram and SB 207499 (ArifloTM, in a Rat Model of Pulmonary Neutrophilia

Author： Spond J.   Chapman R.   Fine J.   Jones H.   Kreutner W.   Kung T.T.   Minnicozzi M.  

Publisher： Academic Press

ISSN： 1094-5539

Source： Pulmonary Pharmacology & Therapeutics, Vol.14, Iss.2, 2001-03, pp. : 157-164

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

ArifloTM(SB 207499), a Second Generation Phosphodiesterase 4 Inhibitor for the Treatment of Asthma and COPD: from Concept to Clinic

By Torphy T.J.   Barnette M.S.   Underwood D.C.   Griswold D.E.   Christensen S.B.   Murdoch R.D.   Nieman R.B.   Compton C.H.  

Pulmonary Pharmacology & Therapeutics, Vol. 12, Iss. 2, 1999-04 ,pp. : 131-135

Academic Press

Access to resources Recommend Favorite

Effects of the phosphodiesterase 4 inhibitors SB 207499 and AWD 12-281 on the inflammatory reaction in a model of allergic dermatitis

By Baumer W.   Gorr G.   Hoppmann J.   Ehinger A.M.   Ehinger B.   Kietzmann M.  

European Journal of Pharmacology, Vol. 446, Iss. 1, 2002-06 ,pp. : 195-200

Elsevier

Access to resources Recommend Favorite

PDE4 inhibitors and chronic obstructive pulmonary disease

By Wolda S.L.  

Expert Opinion on Emerging Drugs, Vol. 5, Iss. 3, 2000-10 ,pp. : 309-319

Informa Healthcare

Access to resources Recommend Favorite

The PDE4 inhibitor rolipram reverses object memory impairment induced by acute tryptophan depletion in the rat

By Rutten K.   Lieben C.   Smits L.   Blokland A.  

Psychopharmacology, Vol. 192, Iss. 2, 2007-06 ,pp. : 275-282

Springer Publishing Company

Access to resources Recommend Favorite

PDE4 inhibitors 1998

By Norman P.  

Expert Opinion on Therapeutic Patents, Vol. 8, Iss. 7, 1998-07 ,pp. : 771-784

Informa Healthcare

Access to resources Recommend Favorite